Re-air Raises ¥580M for Vascular Regeneration Therapy

Tokyo biotech startup Reair Inc., which spun out from Juntendo University, has raised ¥685 million in pre-series A funding. This funding will help advance its regenerative medicine platform. Eight entities invested in the funding round. They included TOPPAN Holdings, Hisamitsu Pharmaceutical, and Asahi Group Japan.

Reair is working on RE-01, a cell therapy. It uses a patient’s own peripheral blood mononuclear cells. This treatment targets refractory ischemic lower limb ulcers. These ulcers are tough to treat with standard methods. The funds will help support the next phase of clinical trials. These investigator-initiated trials are set for 2025. Early trials showed promising results: complete healing of ulcers, less pain, and no harmful events from the therapy. This indicates it is both safe and effective.

Reair will also pursue clinical research for RC-01. This product is an autologous cell-based treatment aimed at diseases linked to microvascular dysfunction. It falls under Japan’s Act on the Safety of Regenerative Medicine.

Also Read: BlueMeme Invests in MediVally for Medical Innovation

This funding is a big step for patient-specific regenerative treatments. It shows more interest in cell therapy for chronic vascular conditions. Reair  focuses on proving its science and meeting regulations. This will help it gain wider acceptance in clinics.